The abstract is read at the publisher; the summary is JClub's.
Siglecs are sialic acid-binding immune lectins that regulate signaling and homeostasis, and their therapeutic potential is still underexplored despite growing mechanistic insight.
- Why it matters: Their central role in immune modulation creates a gap in translating Siglec biology into therapies, especially for cancer and autoimmunity where immunosuppression is a key challenge.
- What they did: This review surveys preclinical work and recent clinical progress, focusing on antibody engineering and glycan biology to map Siglec-ligand interactions, with clinical trials mainly targeting Siglec-2 and Siglec-3 in hematological cancers.
- The result: The evidence suggests Siglec-targeted immunotherapies may regulate immunosuppression in cancer and autoimmunity, and the proposed translational framework aims to accelerate development and broaden immunotherapy advances.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.